Whether immune activation contributes to ADC efficacy in prostate cancer remains unexplored.<h4>Methods</h4>We applied immune-centric design principles to ADC development targeting six transmembrane epithelial antigen of the prostate 1 (STEAP1), a prostate-lineage restricted, androgen receptor-regulated surface antigen. This evidence concerns the gene STEAP1 and prostate cancer.